The Centre for Advanced Therapeutics Early Career Researcher Network is delighted to welcome Dr Tamara Elliott from the Department of Infectious Disease, who will be presenting a talk entitled:
Immune responses to SARS-CoV-2 self-amplifying RNA and mRNA vaccinations in those with and without previous infection
Abstract: Imperial College has developed a SARS-CoV-2 self-amplifying RNA (saRNA) vaccine in lipid nanoparticles (LNP), and the first-in-human trial (COVAC1) started in June 2020. The LNP and structural conformation of spike are identical to the Pfizer mRNA vaccine. The aim of this project is to perform a comparison of the immunological response in those receiving the COVAC1 saRNA vaccine and Pfizer, and to follow COVAC1 participants after they receive an additional approved vaccine. COVAC1 participants who were either COVID-19-naïve or had a history of infection were recruited into a sub-study and additional participants receiving an approved vaccine only were recruited into a comparison group. Antibodies against spike and nucleocapsid protein have been measured using ELISA pre-and post each vaccine dose. After two saRNA vaccine doses 15/18 COVID-19-naïve participants seroconverted (compared to 21/21 for Pfizer). Antibody titres were greatest in those with previous infection receiving two saRNA and two approved vaccine doses.
To sign up to our Newsletter email CAT-ECRfirstname.lastname@example.org
Visit our website to discover more: https://www.imperial.ac.uk/advanced-therapeutics-centre/cat-early-career-network/